Newsletters of 2012
Date Newsletter title Download

1 - 2012
  • Pharmacovigilance Workshop
  • Clopidogrel and proton-pump inhibitors
  • Intravenous Methotrexate – New Safety information

2 - 2012
  • The Pharmacological committee decision about some label changes
  • Strattera (atomoxetine)-- Distribution of Dear Healthcare professional letter in Egypt regarding the increased risk of blood pressure and heart rate
  • Ceftriaxone  use with calcium containing IV solutions in neonates is contraindicated due to the risk of calcium precipitation 

3 - 2012
  • Distribution of Dear Healthcare Professional letter  concerning the Off label use of Avastin
  • Proton Pump Inhibitors (PPIs) - Clostridium Difficile-Associated Diarrhea (CDAD) Can be Associated With Stomach Acid Drugs
  • European Medicines Agency confirms positive benefit-risk balance of orlistat containing medicines

4 - 2012
  • Label changes -- Fluroquinolones, Metoclopramide & Products containing Benzyl alcohol
  • Suspension of marketing authorisations for meprobamate-containing medicines in the EU 
  • European Medicines Agency confirms positive benefit-risk balance of somatropin-containing medicines Prescribers reminded to strictly follow approved indications and doses

5 - 2012
  • Nicotinic acid-- Label Update
  • Miconazole oral gel (Daktarin oral gel) – Interaction with warfarin
  • FDA Issues Warning on Fentanyl Patches

6 - 2012
  • Zaleplon – Restrictions of use in Egypt due to the possibility of its abuse
  • FDA Updates Warnings on Methylene Blue, Linezolid, and Serotonergics
  • FDA approves new antibacterial treatment for plague

7 - 2012
  • Quetiapine Cardiomyopathy – an emerging safety signal
  • Zolpidem tartrate Association with complex sleep behaviours
  • FDA approves Belviq to treat some overweight or obese adults

8 - 2012
  • Cefepime -- Risk of seizure in patients not receiving dosage adjustments for kidney impairment
  • Restrictions on use of pharmaceutical products containing Propylene Glycol
  • Dronedarone – Boxed Warning addition 

9 - 2012
  • FDA warns of risk of death from codeine use in some children following surgeries
  • FDA approves new combination pill for HIV treatment for some patients
  • Regular Aspirin Use Doesn't Reduce Breast Cancer Risk

10 - 2012
  • Sleep Apnea Tied to Insulin Resistance in Young, Lean Men
  • FDA Drug Safety Communication: Rare cases of serious burns with the use of over-the-counter topical muscle and joint pain relievers
  • Candesartan Fetal malformations

11 - 2012
  • Withdrawal of Syrups containing Cyproheptadine with multivitamins
  • FDA: Ongoing safety review of Parkinson’s drug pramipexole and possible risk of heart failure
  • FDA Approves Liquid, Extended-Release ADHD Med
  • Non-steroidal antiinflammatory drugs-- Risk of Severe Cutaneous Adverse Reaction (SCAR) 

12 - 2012
  • Hypotonic Intravenous (I.V.) solution containing 0.18% Saline—New Contraindications
  • Methotrexate label change in Egypt
  • Wellbutrin (Bupropion safety update – possible increased risk of some congenital cardiovascular malformations)
  • Triclosan—Under review due to the risk of endocrine disruption